Safety study of efgartigimod in adults with myasthenia gravis
Observes safety of efgartigimod in adults with generalized myasthenia gravis who take it.
Plain-language title generated from the registry record
Registry title: A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
Key facts
- Where
- Austin, Boca Raton, Boston, Charleston, Detroit, Greenfield, Iowa City, Jacksonville Beach, Kansas City, Louisville, O'Fallon, Port Charlotte, Portland, San Francisco, and St. Petersburg, United StatesSee the 17 sites
Where in United States
- National Neuromuscular Research InstituteAustin, United StatesTaking people
- SFM Clinical Research LLCBoca Raton, United StatesTaking people
- Beth Israel Deaconess Medical CenterBoston, United StatesTaking people
- Massachusetts General HospitalBoston, United StatesTaking people
- Medical University of South CarolinaCharleston, United StatesTaking people
- Henry Ford Health SystemDetroit, United StatesTaking people
- BCN Research, LLC - Gamma Therapeutic CenterGreenfield, United StatesTaking people
- University of IowaIowa City, United StatesTaking people
- University of Florida College of Medicine JacksonvilleJacksonville Beach, United StatesTaking people
- University of Kansas Medical CenterKansas City, United StatesTaking people
- Norton Neuroscience InstituteLouisville, United StatesTaking people
- Prairie Education and Research Cooperative and HSHS Medical GroupO'Fallon, United StatesTaking people
- Medsol Clinical Research Center IncPort Charlotte, United StatesTaking people
- Oregon Health and Science UniversityPortland, United StatesTaking people
- University of Colorado HospitalPortland, United StatesTaking people
- UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center - Brain Tumor Center,San Francisco, United StatesTaking people
- BayCare Health System, Inc. St Anthony's HospitalSt. Petersburg, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- argenx
- Trial code
- NCT06298565
- Record updated
- 17 February 2026
- Original description
This is a non-interventional, prospective, post authorization safety study. Patients with gMG who are expected to start treatment with efgartigimod at enrolment or are within their first cycle of efgartigimod at enrolment will be eligible to enroll into the efgartigimod cohort. Patients with gMG who have not been exposed to efgartigimod and for whom it is not planned to start treatment with efgartigimod at enrolment will be eligible to enroll into the non-efgartigimod cohort.Read full original descriptionShow less
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
This is a non-interventional, prospective, post authorization safety study. Patients with gMG who are expected to start treatment with efgartigimod at enrolment or are within their first cycle of efgartigimod at enrolment will be eligible to enroll into the efgartigimod cohort. Patients with gMG who have not been exposed to efgartigimod and for whom it is not planned to start treatment with efgartigimod at enrolment will be eligible to enroll into the non-efgartigimod cohort.
Inclusion: Patients diagnosed with gMG who are expected to start commercial efgartigimod at enrolment or who are within their first cycle of efgartigimod at enrolment or Patients diagnosed with gMG who have not been exposed to efgartigimod and for whom it is not planned to start treatment with efgartigimod at enrolment; Have provided appropriate written informed consent.
Exclusion: None.